Autor segons l'article: Razquin C; Ruiz-Canela M; Clish CB; Li J; Toledo E; Dennis C; Liang L; Salas-Huetos A; Pierce KA; Guasch-Ferré M; Corella D; Ros E; Estruch R; Gómez-Gracia E; Fitó M; Lapetra J; Romaguera D; Alonso-Gómez A; Serra-Majem L; Salas-Salvadó J; Hu FB; Martínez-González MA
Departament: Bioquímica i Biotecnologia
Autor/s de la URV: Salas Huetos, Albert / Salas Salvadó, Jorge
Paraules clau: biomarkers cardiovascular disease dietary intervention metabolites 2-aminoadipic acid Biomarkers Cardiovascular disease Dietary intervention Metabolites Prevention Type 2 diabetes
Resum: BACKGROUND: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. METHODS: Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. RESULTS: In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. CONCLUSIONS: Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003.
Àrees temàtiques: Biotecnología Cardiac & cardiovascular systems Cardiology and cardiovascular medicine Ciências biológicas i Ciências biológicas ii Educação física Endocrinology & metabolism Endocrinology, diabetes and metabolism Farmacia Interdisciplinar Internal medicine Medicina i Medicina ii Saúde coletiva
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: jordi.salas@urv.cat albert.salas@urv.cat
ISSN: 14752840
Identificador de l'autor: 0000-0003-2700-7459 0000-0001-5914-6862
Data d'alta del registre: 2023-02-18
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Referència a l'article segons font original: Cardiovascular Diabetology. 18 (1): 151-
Referència de l'ítem segons les normes APA: Razquin C; Ruiz-Canela M; Clish CB; Li J; Toledo E; Dennis C; Liang L; Salas-Huetos A; Pierce KA; Guasch-Ferré M; Corella D; Ros E; Estruch R; Gómez-G (2019). Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies. Cardiovascular Diabetology, 18(1), 151-. DOI: 10.1186/s12933-019-0958-2
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2019
Tipus de publicació: Journal Publications
Repositori URV